ReviewEuropean respiratory review : an official journal of the European Respiratory Society2016
KRAS oncogene in lung cancer: focus on molecularly driven clinical trials.
Review in European respiratory review : an official journal of the European Respiratory Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 83 citations in OpenAlex.
- Loss of PIK3CA AllowsCells · 2026Article
- Loss of PIK3CA allowsbioRxiv : the preprint server for biology · 2026Article
- Pancreatic cancer in the era of precision medicine: challenges, advances, and the future of therapeutic strategies.Journal of the Egyptian National Cancer Institute · 2025Review
- Oxypalmatine promotes apoptosis and protective autophagy in lung cancer cells via the PI3K/AKT pathway.Cancer cell international · 2025Article
- Dual inhibition of GTP-bound KRAS and mTOR in lung adenocarcinoma and squamous cell carcinoma harboring KRAS G12C.Cell communication and signaling : CCS · 2025Article
- Impact of KRASClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis.British journal of cancer · 2024Article
- Recent advances in molecular targeted therapy of lung cancer: Possible application in translation medicine.Iranian journal of basic medical sciences · 2024Review
- Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States.The oncologist · 2023Article
- Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor.Pharmacological reviews · 2023Review
- Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer.Pharmaceutics · 2023Review
- A Novel Combination of Sotorasib and Metformin Enhances Cytotoxicity and Apoptosis in KRAS-Mutated Non-Small Cell Lung Cancer Cell Lines through MAPK and P70S6K Inhibition.International journal of molecular sciences · 2023Article
- Machine learning multi-omics analysis reveals cancer driver dysregulation in pan-cancer cell lines compared to primary tumors.Communications biology · 2022Article
- Review
- Thoracic Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner.Journal of the advanced practitioner in oncology · 2022Article
- A pharmacological exploration of targeted drug therapy in non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2022Review
- Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review.Cancers · 2022Review
- Characteristics of Women with Lung Adenocarcinoma in the World Trade Center Environmental Health Center.International journal of environmental research and public health · 2022Article
- Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2022Article
- The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia.F1000Research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
KRAS mutations are the most frequent molecular abnormalities found in one out of four nonsmall cell lung cancers (NSCLC). Their incidence increases in cases of adenocarcinoma, smokers and Caucasian patients. Their negative value in terms of prognosis and responsiveness to both standard chemotherapy and targeted therapies remains under debate. Many drugs have been developed specifically for KRAS-mutated NSCLC patients. Direct inhibition of RAS activation failed to show any clinical efficacy. Inhibition of downstream targets of the mitogen-activated protein kinase (MEK) pathway is a promising strategy: phase II combinations of MEK 1/2 kinase inhibitors with chemotherapy doubled patients' clinical outcomes. One phase III trial in such a setting is ongoing. Double inhibition of MEK and epidermal growth factor receptor proteins is currently being assessed in early-phase trials. The association with mammalian target of rapamycin pathway inhibition leads to non-manageable toxicity. Other strategies, such as inhibition of molecular heat-shock proteins 90 or focal adhesion kinase are currently assessed. Abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, showed promising results in a phase I trial, with a 54% disease control rate. Results of an ongoing phase III trial are warranted. Immunotherapy might be the next relevant step in KRAS-mutated NSCLC management due to the high burden of associated mutations and neo-antigens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.